Two Sigma Investments
OBIO icon

Two Sigma Investments’s Orchestra BioMed OBIO Stock Holding History

Two Sigma Investments’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$255K Sell
60,107
-26,445
-31% -$113K ﹤0.01% 4165
2025
Q4 		$359K Buy
+86,552
New +$349K ﹤0.01% 3498

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Two Sigma Investments's OBIO Position: Q1 2026 in Review

Two Sigma Investments reduced its Orchestra BioMed (OBIO) stake by 31% in Q1 2026, selling an estimated $113K and leaving 60,107 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #4165.

Two Sigma Investments first reported a position in OBIO in Q4 2025 and has held it in 2 quarters since. The position peaked at $359K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Two Sigma Investments held 60,107 shares of Orchestra BioMed worth $255K as of Q1 2026.
  • Two Sigma Investments sold 26,445 Orchestra BioMed shares in Q1 2026, an estimated $113K.
  • Orchestra BioMed made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #4165 holding.
  • Two Sigma Investments first reported a position in Orchestra BioMed in Q4 2025 and has held it in 2 quarters since.
  • Two Sigma Investments's Orchestra BioMed position peaked at $359K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.